BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.2026-06-25 13:46 ESTEarnings

SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S.

Open original release

Related news

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming December Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics to Present at Upcoming February Conferences

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

CTMXCytomX Therapeutics, Inc.2026-06-25 13:46 EST

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

View all latest news

CytomX Therapeutics, Inc.

CytomX Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CTMXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CTMXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CTMXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CTMXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CTMXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
3.70 USD
Market cap
818.56M USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States